Mistral Pharma Inc.

Mistral Pharma Inc.

November 14, 2005 14:04 ET

Mistral Pharma to Present at BioFinance 2005

MONTREAL, QUEBEC--(CCNMatthews - Nov. 14, 2005) - Mistral Pharma Inc. (TSX VENTURE:MIP) announced today that it will be a presenter at the BIOFINANCE 2005 conference at the MaRS Center in Toronto. This presentation will be given by Mr. Bertrand Bolduc, President and Chief Executive Officer of Mistral Pharma on November 16, 2005 in the CR-3 room at 11:40 a.m. (Toronto time).

"This is a great opportunity to showcase Mistral Pharma to the Canadian investment community and to present our exciting projects and commercial partnerships" commented Bertrand Bolduc. "Our recent financing and listing on the TSX Venture Exchange gives Canadian investors a very interesting investment opportunity in a growing field" he added.

About BioFinance

BioFinance Early Phase 2005 is a one-day program that will feature presentations by the CEOs from 36 emerging life science companies from across Canada and the US. It will also feature panel discussions by experts on topics including early stage financing, aspects of the deal and US financing sources. The presenting companies will be developing new medicines, devices, diagnostics, medical technologies and systems. These companies will likely have some angel, private or seed financing already in place and will be starting the search for investment in the range of up to $ 2 to 5 million. For more information visit the BioFinance website at www.biofinance.com

About Mistral Pharma Inc.

Mistral Pharma is an emerging oral drug delivery company which develops generic and branded controlled-delivery products using its PROCISE™, SAVIT™ and CHRONOP™ geometry surface area technologies. These technologies offer many competitive advantages including flexible and fast development, competitive cost of goods and the use of "generally recognized as safe" excipients. Additional information about Mistral Pharma can be obtained from Mistral Pharma's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on suppositions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information